Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (FENC)
NASDAQ:FENC
FENC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.96 - $11.11
Previous Close$6.08
Volume58.66K
Average Volume (3M)100.12K
Market Cap
$162.88M
Enterprise Value$229.47M
Total Cash (Recent Filing)$348.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.13
Next Earnings
May 08, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding27,594,007
10 Day Avg. Volume84,617
30 Day Avg. Volume100,117
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.67
Price to Cash Flow (P/CF)-20.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.48
Enterprise Value/Ebitda49.14
Forecast
1Y Price Target
$14.00Price Target Upside150.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Fennec Pharmaceuticals News
PremiumCompany Announcements
Fennec Pharmaceuticals Reports Strong Growth Amid Challenges
PremiumCompany Announcements
Fennec Pharmaceuticals Reports Strong 2024 Sales Growth
---
Bulls Say, Bears Say
Bulls Say
CommercializationEuropean commercial rollout advancing with Fennec's partner Norgine receiving positive guidance from NICE and launching PEDMARQSI in Germany.
Market ExpansionFennec remains poised to reap benefits from market expansion to the adolescent and young adult (AYA) community with payor reimbursement, as well as product adoption within prominent academic centers, including Cedars-Sinai in Los Angeles, CA and Mount Sinai in New York, NY.
Reimbursement SuccessFennec surpassed 90% reimbursement in the AYA population for PEDMARK in 3Q24, indicating a strong position in this significant market segment.
Bears Say
Financial PerformanceFennec Pharmaceuticals' 3Q24 financial results missed revenue and bottom-line forecasts, indicating challenges in meeting financial expectations.
Quarterly RevenueThe company recorded product revenue totaling only $7M, which actually represented a modest quarter-over-quarter decline vs. 2Q24.
Revenue ProjectionsThe full-year 2025 total revenue estimate has been modestly reduced to $46.7M from the prior estimate of $48.4M.
---
Ownership Overview
1.70% Insiders
5.12% Mutual Funds
― Other Institutional Investors
86.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FENC FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was $3.96 and its highest was $11.11 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is $162.88M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is May 08, 2025 which is in 33 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Mar 10, 2025. The company reported -$0.061 earnings per share for the quarter, beating the consensus estimate of -$0.13 by $0.069.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is -0.09.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 27,594,007 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of -$0.061 in its last earnings report, beating expectations of -$0.13. Following the earnings report the stock price went down -11.192%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in FENC
---
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (150.45% Upside)
$14.00 (150.45% Upside)
Blogger Sentiment
Bullish
FENC Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $46.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
67.31%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
---
FENC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, successful international launches, and strong financial management. However, increased operating expenses and challenges in awareness and adoption of PEDMARK, particularly in the AYA segment, were noted.Read More>---
FENC Stock 12 Month Forecast
Average Price Target
$14.00
▲(150.45% Upside)
Technical Analysis
Best Analysts Covering FENC
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-5.99%
reiterated a buy rating 6 months ago
Copying Naureen Quibria's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -5.99% per trade.
---